A Phase 4 interventional study of Empagliflozin+Linagliptin+Metformin in Diabetes Mellitus and Type 2 DM, sponsored by Nabiqasim Industries (Pvt) Ltd. Recruiting at 2 sites in Pakistan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Nabiqasim Industries (Pvt) Ltd · Phase 4, Interventional, and Treatment
Among 40 studies testing empagliflozin in Diabetes Mellitus — 8 open to participants now, 8 under way, none of them phase 3. empagliflozin · Diabetes Mellitus.
Among the 40 studies testing empagliflozin in Diabetes Mellitus, this one has the largest planned enrollment, is one of 3 that started in 2025, is one of 23 in phase 4, and was the 33rd registered.
8,291 studies on the registry are indexed under Diabetes Mellitus; 1,075 are open to participants now.
Browse Diabetes Mellitus studies →8 of the 40 studies testing empagliflozin in Diabetes Mellitus are open now, in 4 countries. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 18–70
Mayo Clinic · Sites in United States
Ages 18–80
VA Office of Research and Development · Sites in United States
Ages 19+
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 20+
Medanta, The Medicity, India · Sites in India
Ages 30+
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 649 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 80 across 6,024 interventional studies indexed under Diabetes Mellitus.
Median enrollment 62 across the 40 interventional studies. Of the 23 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 40 have an industry lead sponsor. The 10 most frequent:
Nabiqasim Industries (Pvt) Ltd is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Nabiqasim Industries (Pvt) Ltd has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
2 of the studies testing empagliflozin in Diabetes Mellitus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06729996Mayo ClinicPioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus | 2027-05-31 |
| NCT07155694Washington D.C. Veterans Affairs Medical CenterRole of Finerenone in African American Veterans With Diabetic Kidney Disease | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 40 studies testing empagliflozin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.
This study aims to demonstrate that a poly-pill approach combining metformin, linagliptin, and empagliflozin will provide an effective and safe treatment option for managing type 2 diabetes mellitus (T2DM). By focusing on the reduction of HbA1c levels and enhancing patients' quality of life, this simplified approach is expected to streamline medication regimens, reduce pill burden, and improve treatment adherence. Furthermore, the study anticipates that this combination therapy will positively influence weight management and lower the incidence of hypoglycemic events, addressing common challenges in T2DM management. As T2DM prevalence continues to rise, especially in low- and middle-income countries, the poly-pill strategy may offer significant benefits, promoting better compliance, affordable low-in-cost treatment, and facilitating improved long-term health outcomes. Through this research, the study intends to provide strong evidence supporting the poly-pill regimen as a viable and impactful option for global T2DM management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Empagliflozin (25 mg) Linagliptin (5 mg) Metformin XR (1000 mg) once daily combination therapy
Combination Product: Empagliflozin+Linagliptin+Metformin
Drug pages: Empagliflozin · Linagliptin · Metformin
Scarcity of local population data on triple drug combination's impact on compliance, efficacy and safety in diabetic patients
Changes in HbA1c levels
Metabolic control
Time frame: 03 months, 06 months
Change in scores of Quality of Life-Short Form "SF-36" questionnaire
Improvement in quality of life (before and after treatment)
Time frame: 06 months
Changes in Diabetic Treatment Satisfaction Questionnaire "DTSQ"
Diabetic treatment satisfaction level (before and after treatment)
Time frame: 06 months
Hypoglycemic events
Hypoglycemic events frequency and severity of hypoglycemic events
Time frame: 06 months
Changes in body weight
Increase or decrease in body weight
Time frame: 03 and 06 months
Plan to share: No
Started Oct 2025 (actual). Primary completion is estimated for Apr 2026, 6 months after the start.
Of 48 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's planned 6 months is below that.
Counting every sponsor, half of 197 studies reached it within 24 months; a quarter within 13 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Empagliflozin · Linagliptin · Metformin
Nabiqasim Industries (Pvt) Ltd